Radiation-Free Microwave Technology for Breast Lesion Detection Using Supervised Machine Learning Model

This work demonstrates that Machine learning (ML) can help understand phenomena from the frequency spectrum collected through MammoWave in response to the stimulus, segregating breasts with and without lesions.

Mammography is the gold standard technology for breast screening, which has been demonstrated through different randomized controlled trials to reduce breast cancer mortality. However, mammography has limitations and potential harms, such as the use of ionizing radiation. To overcome the ionizing radiation exposure issues, a novel device (i.e. MammoWave) based on low-power radio-frequency signals has been developed for breast lesion detection. The MammoWave is a microwave device and is under clinical validation phase in several hospitals across Europe. The device transmits non-invasive microwave signals through the breast and accumulates the backscattered (returned) signatures, commonly denoted as the S21 signals in engineering terminology. Backscattered (complex) S21  signals exploit the contrast in dielectric properties of breasts with and without lesions. The proposed research is aimed to automatically segregate these two types of signal responses by applying appropriate supervised machine learning (ML) algorithm for the data emerging from this research. The support vector machine with radial basis function has been employed here. The proposed algorithm has been trained and tested using microwave breast response data collected at one of the clinical validation centres. Statistical evaluation indicates that the proposed ML model can recognise the MammoWave breasts signal with no radiological finding (NF) and with radiological findings (WF), i.e., may be the presence of benign or malignant lesions. A sensitivity of 84.40% and a specificity of 95.50% have been achieved in NF/WF recognition using the proposed ML model.

 

Download the publication

Share the Post:

You might be interested in

Issue #1 of the MAMMOSCREEN newsletter is finally out!  

Read more

Interview with Siobhán Freeney, patient advocate on breast cancer.

Read more

Meet the MAMMOSCREEN Team: Fondazione Toscana Life Sciences  

Read more